3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
44
Breast Neoplasms
42
Lung Neoplasms
27
Carcinoma, Non-Small-Cell Lung
21
Colorectal Neoplasms
19
Uterine Cervical Neoplasms
13
Prostatic Neoplasms
13
Ovarian Neoplasms
11
Head and Neck Neoplasms
11
Carcinoma, Hepatocellular
11
Pancreatic Neoplasms
10
Melanoma
10
Brain Neoplasms
9
Sarcoma
7
Neoplastic Cells, Circulating
7
Myelodysplastic Syndromes
7
Glioma
7
Esophageal Neoplasms
7
Endometrial Neoplasms
7
Multiple Myeloma
6
Gastrointestinal Neoplasms
6
Disease
6
Carcinoma, Renal Cell
6
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Uveal Melanoma
4
Skin Neoplasms
4
Neoplasm, Residual
4
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Blood Specimen Collection
×
1 year
×
Clear all
NCT04253080
2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
127 enrolled